Biogroup - Good to be boring - 26Q3 - Model Update

All,

Following the pricing agreement reached between CNAM and the French medical biologists, BioGroup can now refocus on delivering further cost savings and sustaining the recent improvements in EBITDA. The May refinancing removed near-term maturities, while the new three-year pricing framework provides considerably greater visibility on the regulatory environment. There is now limited near-term event risk in the name. That said, sometimes it is nice to be exposed to a stable business with a healthy 7% yield.

Investment Rationale

  • We are not taking a position in the newly issued €1.3bn 7.5% 2031 bonds. Trading slightly above par, the bonds offer limited near-term downside protection, but at a yield of c.7% it does not meet our internal hurdle rate. However, we acknowledge there is limited downside and at 7%, are compensated for the risks involved.

  • We exited our position in the Senior Unsecured bonds at 94%, ahead of the Company launching the A&E transaction, which moved the capital structure to an all-senior format with maturities in 2031.

  • We had expected some further tightening following greater clarity from the French state on pricing. However, any idiosyncratic improvement has since been offset by broader market widening. That said, the bonds are materially less risky today than they were at the time of the refinancing.

  • Downside is now largely driven by broader market conditions. There remains a risk of a further price adjustment next summer, but we expect the impact to be limited and do not view this as a major concern.

Recent Results

  • BioGroup delivered another solid quarter, with revenue up 5.6% and EBITDA up 8.0%, reflecting continued delivery of the transformation plan. The Company has now delivered €146m of its €200m savings target, with a further €42m of EBITDA impact expected. FY26 guidance was upgraded, while FY27 guidance points to revenue growth of c.2% and an EBITDA margin above 27.5%.

  • The refinancing has removed near-term maturity risk, with all term debt now due in August 2031. However, leverage remains elevated at 5.4x secured and 5.5x unsecured, based on the Company's €504m leverageable EBITDA. Using our more conservative EBITDA figure, we calculate leverage at 5.8x.

  • The regulatory backdrop has improved, with the French industry agreeing a new three-year reimbursement protocol for 2027–29. This provides greater visibility on pricing and removes some of the uncertainty that dominated previous quarters, although a further tariff adjustment remains possible from Q2 2027.

  • Cash generation remains solid, with €273m of operating free cash flow generated in the first nine months, equivalent to 80% of EBITDA. However, minority put obligations remain material at €209m, while interest costs have increased following the refinancing.

French Pricing Agreement

  • On 2 November, the French National Health Insurance (CNAM) and the representative unions of medical biologists signed a new three-year pricing protocol covering 2027–29. This represents a meaningful improvement on the previous arrangement, which largely locked in the lower test prices introduced in September 2024 through to December 2026.

  • The new framework provides greater visibility on reimbursement, with the routine biology budget set to increase by 1.9% per annum. In addition, a €100m innovation fund will be introduced over the three years (€40m in 2027, €35m in 2028 and €25m in 2029), funding new reimbursable tests.

  • Management estimates that this will support French market growth of c.1.6% in 2027, comprising 1.1% from routine activity and a further 0.5% from innovation. This is a relatively cautious assumption, with management acknowledging that the innovation contribution could ultimately be higher as implementation progresses.

  • The agreement materially reduces the risk of a repeat of the abrupt pricing intervention seen in September 2024. However, it does not entirely remove the possibility of further price adjustments. Management does not expect a price cut on 1 January 2027, as CNAM will first need to review the final 2026 activity and expenditure figures, likely in March or April. Any adjustment, if required and within the terms of the new protocol, would therefore be expected in Q2 or potentially early July 2027. The size of any adjustment has not been quantified.

  • Importantly, management does not expect the agreement itself to be reopened following the May 2027 presidential election, highlighting the state's commitment to the three-year framework. Overall, the new regime provides considerably greater pricing visibility and reduces the risk of another significant industry-wide tariff cut, although some residual uncertainty remains around the mid-2027 review.

Happy to discuss.

Tomas

Tomás MannionBIOGROUP